AbbVie Inc.
ABBVHealthcare
$233.21
+0.49%
Price History (1 Year)
Market Cap
$412.4B
P/E Ratio
98.4x
P/B Ratio
-125.12x
EV/EBITDA
16.7x
ROE
-129.2%
FCF Yield
4.4%
Div. Yield
2.96%
DCF Value
$200.11
Overvalued vs DCF
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025-12-31 | $16.62B | $1.82B | $1.02 |
| 2025-09-30 | $15.78B | $186M | $0.10 |
| 2025-06-30 | $15.42B | $938M | $0.53 |
| 2025-03-31 | $13.34B | $1.29B | $0.72 |
AI Analysis
ABBV: Why the 9% Selloff Creates a Buying Window
- •AbbVie's 9% pullback to $205 creates an attractive entry at 12.9x 2027 estimated earnings with a 3.2% dividend yield, backed by $17.8 billion in annual free cash flow.
- •The Humira transition is working — FY2025 revenue grew 8.7% to $61.2 billion as Skyrizi and Rinvoq ramp faster than Humira erodes, with Q4 delivering a record $16.6 billion quarter.
- •The trailing P/E of 86x is an optical distortion from Allergan acquisition amortization; forward estimates show AbbVie trading at a meaningful discount to the healthcare sector.
Read full analysis →
Healthcare Peers
Data provided by Financial Modeling Prep. AI analysis generated by Claude. This is not financial advice. Past performance does not guarantee future results. Always do your own research before making investment decisions.